Content |
Assets
History
2022
Gilead bought a developer of drugs to restore the immune balance for $405 million
MiroBio is a private clinical-stage biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint antibody agonists, to restore immune balance in patients with autoimmune diseases. Read more here
Payment of $1.25 billion to GlaxoSmithKline for theft of HIV drug development
On February 2, 2022, it became known that the British company GlaxoSmithKline (GSK) will receive $1.25 billion from Gilead Sciences as part of a settlement between its drug development unit HIV ViiV Healthcare and GSK.
The settlement announced by GSK concerns the antiretroviral drug Gilead Biktarvy, a drug used to test for viruses that cause AIDS, which GSK said in 2018 violated the rights to dolutegravir and other similar compounds of its ViiV Healthcare unit.
In accordance with the agreement, Gilead will pay $1.25 billion to GSK ViiV Healthcare in the first quarter of 2022. In addition, the company will pay 3% royalties on U.S. sales of the widely marketed HIV drug Biktarvy before the GSK patent expires in October 2027.
GSK, Pfizer and Shionogi, each holding a stake in ViiV, will receive a portion of the income from payments and royalties in proportion to their shares.
In a message to clients, Jefferies analyst Peter Welford said the deal provides "welcome growth potential" for GSK as it prepares to partition the consumer healthcare sector. The analyst cited "rough" math to suggest that Biktarvy will generate about $50 billion in the United States from February 2022 to October 2027. This means that the licensed part of the transaction at the time of settlement is about £1.45 billion ($1.97 billion), the analyst wrote.
In the patent dispute, ViiV Healthcare and its shareholders GSK and Shionogi said Gilead's Biktarvy violated their dolutegravir-related patents. Gilead is a combination of bictegravir, tenofovir alafenamide, and emtricitabine.
Through the settlement, Gilead will receive a global license for certain patents related to the ViiV drug. ViiV and its shareholders agreed not to apply the patents "in connection with any past or future infringement claims relating to Biktarvy" or any products containing biktegravir.[1]
Cancer drug recall due to deadly side effects
On January 14, 2022, the American biopharmaceutical company Gilead Sciences notified the regulator health care USA of its decision to voluntarily abandon the use of its drug Zydelig for the treatment of two types, namely cancer follicular lymphoma and small lymphocytic. leukemias More. here
2020
Purchase of German biotech firm MYR Pharmaceuticals
In early December 2020, Gilead Sciences announced the acquisition of the German biotechnology firm MYR Pharmaceuticals for €1.15 billion with a possible surcharge of up to €300 million. The deal ensured the rapid growth of Gilead Sciences shares amid the registration of the drug remdesivir for the treatment of COVID-19. Read more here.
Buying Immunomedics
On September 14, 2020, Gilead announced the purchase of Immunomedics for $21 billion. The value of the transaction in terms of one share of the sold company is $88, which is 108% more than the rate of quotations by the closing of the exchange on September 11. Read more here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |